retatrutide biotechpeptides.com Retatrutide: Triple-Agonist for Obesity and

Trusted by healthcare professionals, Retatrutide combines scientific innovation and convenience to help you manage appetite, burn fat efficiently, and reach your weight-loss goals

Clinical trials indicate retatrutide subcutaneous fat loss

COA / Lab results Evidence: Clinical trial Pros Triple GLP-1 / GIP / glucagon agonism in one peptide raises energy expenditure, not appetite alone Largest weight reduction reported for an incretin-class compound (~24% at 12 mg, 48-wk phase 2) Reductions in HbA1c, visceral fat and liver-fat content across trials Once-weekly subcutaneous dosing (albumin-bound half-life) Cons GI effects require gradual multi-week dose titration Newest of the GLP-1 class phase 3 (TRIUMPH) topline only

Maxes out a U-100 syringe 20 mg/mL (1.5 mL diluent): 12 mg draws to 0.60 mL (60 units)

While genetic variations in receptor expression may theoretically affect response, this is not currently used in clinical decision-making